2838. Safety and Immunogenicity of a gp120-CD4 Chimeric Subunit Vaccine: A Phase 1a Randomized Controlled Trial

por Chua, Joel V, Davis, Charles, Nelson, Amy, Lam, Ka Wing J, Mutumbi, Lydiah, Stafford, Kristen A, Gilliam, Bruce, DeVico, Anthony L, Lewis, George K, Sajadi, Mohammad M
Publicado 2019

Short‐duration treatment with the novel non‐nucleoside inhibitor CDI‐31244 plus sofosbuvir/velpatasvir for chronic hepatitis C: An open‐label study

por Chua, Joel V., Ntem‐Mensah, Afua, Abutaleb, Ameer, Husson, Jennifer, Mutumbi, Lydiah, Lam, Ka Wing, Ghosh, Alip, Romani, Sara, Poonia, Bhawna, Lee, Sam, Luz Pascual, M., Frumkin, Lyn R., Kottilil, Shyamsundaran
Publicado 2020

Safety and immunogenicity of an HIV-1 gp120-CD4 chimeric subunit vaccine in a phase 1a randomized controlled trial

por Chua, Joel V., Davis, Charles, Husson, Jennifer S., Nelson, Amy, Prado, Ilia, Flinko, Robin, Lam, Ka Wing J., Mutumbi, Lydiah, Mayer, Bryan T., Dong, Dan, Fulp, William, Mahoney, Celia, Gerber, Monica, Gottardo, Raphael, Gilliam, Bruce L., Greene, Kelli, Gao, Hongmei, Yates, Nicole, Ferrari, Guido, Tomaras, Georgia, Montefiori, David, Schwartz, Jennifer A., Fouts, Timothy, DeVico, Anthony L., Lewis, George K., Gallo, Robert C., Sajadi, Mohammad M.
Publicado 2021